Innovative Therapies Days 2025

8:30 : REGISTRATION AND WELCOME COFFEE

9:00 : WELCOME ADRESS

Dr Sylvain Perruche, Med’Inn’Pharma, Besançon, FR
Renaud Gaudillière, PMT director 

09:15 : KEYNOTE : Designing scalable Cell Therapy operations from day one
Dr Rach Fayad, KPMG, Zurich, CH

9:45 – 12:00 : SESSION #1 « RESEARCH TO PROOF OF CONCEPT »
Chairpersons : Pr John De Vos, CHU Montpellier and xx, FR

09:45 : Engineering iPSC-derived immune cells
Dr Sjoukje van der Stegen, Chan Zuckerberg BioHub, New-York, USA

10:15 : BREAK – EXHIBITION HALL

11:00 : CeBBOc: a case study in Occitanie in building a regional cell-based biotherapy ecosystem
Pr John De Vos, CHU Montpellier, FRA 

11:10 : Extracellular vesicles from iPSC-derived MSCs : An innovative biotherapy for osteoarthritis?
Pr Danièle Noël, IRMB, Montpellier, FRA 

11:40 : From spontaneous regeneration to cellular engineering: towards iChondrocyte therapy of articular cartilage
Dr Farida Djouad, IRMB, Montpellier, FRA 

12:10-14:00 : LUNCH

12:30-14:30 : EXHIBITION HALL – B2B MEETINGS 

14:15-14:45 : SYMPOSIUM CYTIVA

Simon Quenneville and Charles Chesnelong 

14:45-17:30 : SESSION #2 « PROOF OF CONCEPT TO CLINIC »

Chairpersons : Dr Jessica Gobbo, CTM Inserm Dijon and xx, FR 

14:45 : SGC off-the-shelf innovative immunotherapy to treat cancer : from bench to bedside
Dr George Alzeeb, Brenus Pharma, Lyon, FRA 

15:15 : Biotherapies based on extracellular vesicles: from research to innovation
Dr Amanda Silva-Brun, CNRS Université Paris Cité, Paris, FRA 

15:45 : GOLD SPONSOR SMALL TALK

15:50 : BREAK – EXHIBITION HALL 

16:30 : Nonclinical development of in vivo CAR-T for autoimmune diseases
Dr Ana Bejanariu, Sanofi, Paris, FRA

17:00 : From Bench to Bedside: Regulatory Strategies and Development Tools to Streamline the Transition from Non-
Clinical to Clinical for Emerging Biotechs

PharmD Damia Benchabane, Alira Health, Paris, FRA 

17:45-18:45 : OFFICIAL DELEGATION TOUR 

17:45-22:00 : POSTER’S SESSION 

18:45-22:00 : NETWORKING COCKTAIL

Opening by representative of the President of Grand Besançon Métropole & representative of the President of the Bourgogne
Franche Comté Region

8:30 :  WELCOME COFFEE  (KURSAAL)

KEYNOTE : Mabdesign

 9:15-12:00 :  SESSION #3 : Early-Stage Clinical Trials

Chairpersons : Dr Sylvain Perruche, Med’Inn’Pharma and xx, FR 

 09:15 : CAR-T cell in autoimmune diseases: from the laboratory to clinical applications 

Pr Dominique Farge-Bancel, CRMR MATHEC, Hôpital St-Louis, AP-HP, Université Paris Cité, Paris, FR

 09:45 : Translating MSC Exosome Science into Therapy: Preclinical Evidence and First-in-Human Trial for Psoriasis

Pr Sai Kiang Lim, Paracrine Therapeutics, Singapour

 10:15 : BREAK- EXHIBITION HALL

 11:00 : The challenges of translating Pluripotent Stem Cell-derived therapies compared to somatic cell therapies: from starting material to product purity

Dr Jo Mountford, Scottish National Blood Transfusion Service, Edinburgh, UK

11:30 : ATMP regulation in the USA: how does it differ from the EU?

Pr Erika Lietzan, University of Missouri-Columbia, Columbia, USA

 12:00-14:00 : LUNCH & Exhibition Hall

12:30-13:50 : B2B MEETINGS

14:00-16:30 : SESSION #4 : SCALE-UP AND GO TO MARKET

Chairpersons : Dr Christophe Ferrand and Dr Marina Deschamps, Right Institute, Besançon, FR

 14:00 : Journey of India’s First Indigenous CAR-T Therapy

Dr Rahul Purwar, ImmunoACT, Bombay, India

 14:30 :  Upcoming title (Innovation for scalable CAR-T production)

Guillaume Wallart, Cellquest, Besançon, FRA

 15:00 : BREAK- EXHIBITION HALL

 15:30 : ATMP release : from phase I to commercial stage

Dr Hélène Nègre, CELLforCURE by SEQENS, Les Ulis, FRA

16:00 : CAR-T therapy for adult ALL: opportunities and challenges

Dr Claire Roddie, Autolus, London, UK

16:45-16:50 : CONCLUSION & END OF CONGRESS

Dr Marina Deschamps, RIGHT Institute, Besançon, FR

Renaud Gaudillière, PMT director